Trial · NCT07904104
Late Low-Dose Dexamethasone in Preterm Neonates Using DART Protocol
NCT07904104, Not applicable, Completed, Shaheed Zulfiqar Ali Bhutto Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Late Low-Dose Dexamethasone in Preterm Neonates Using DART Protocol. Trials, record NCT07904104. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904104
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Late Low-Dose Dexamethasone in Preterm Neonates Using DART Protocol
- NCT number
- NCT07904104
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 93 participants, actual
- Lead sponsor
- Shaheed Zulfiqar Ali Bhutto Medical University
- Conditions
- Bronchopulmonary Dysplasia (BPD)
- Interventions
- Dexamethasone
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Fraction of Inspired Oxygen (FiO₂) | Baseline before the first dexamethasone dose and day 10 after treatment initiation. | Change in the fraction of inspired oxygen required for respiratory support from baseline before dexamethasone initiation to treatment day 10. FiO₂ is expressed as a fraction from 0.21 to 1.00. A lower value indicates a lower supplemental oxygen requirement. |
| Primary | Change in Mean Airway Pressure | Baseline before the first dexamethasone dose and day 10 after treatment initiation. | Change in mean airway pressure, measured in cmH₂O, from baseline before dexamethasone initiation to treatment day 10. A lower value indicates a reduction in the airway pressure used for respiratory support. |
| Primary | Successful Extubation Within 10 Days | Within 10 days after the first dexamethasone dose. | Number of infants successfully extubated from invasive mechanical ventilation within 10 days after dexamethasone initiation. |
| Primary | Time to Successful Extubation | From dexamethasone initiation through day 10. | Time in days from the first dexamethasone dose to successful extubation from invasive mechanical ventilation. |
| Primary | Total Duration of Ventilatory Support | 20 days | Total number of days during which an infant received invasive mechanical ventilation and/or non-invasive ventilation. |
| Primary | Total Duration of Supplemental Oxygen Therapy | 20 days | Total number of days during which an infant received supplemental oxygen. |
| Primary | Pulmonary Haemorrhage During Treatment | From the first dexamethasone dose until treatment discontinuation or completion, up to 10 days. | Number of infants who developed pulmonary haemorrhage during dexamethasone treatment. |
| Primary | Intraventricular Haemorrhage During Treatment | From the first dexamethasone dose until treatment discontinuation or completion, up to 10 days. | Number of infants with newly detected or worsening intraventricular haemorrhage during dexamethasone treatment, assessed using cranial ultrasonography. |
| Primary | All-cause Mortality During Treatment | From the first dexamethasone dose through day 10. | Number of infants who died from any cause during the dexamethasone treatment period. |
| Secondary | Bronchopulmonary Dysplasia Status and Severity | At 36 weeks' postmenstrual age. | Number of infants in each bronchopulmonary dysplasia category: no bronchopulmonary dysplasia, mild, moderate, or severe, classified using the National Institutes of Health criteria specified in the study protocol. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904104
GET https://conductscience.org/api/trials/v1/NCT07904104/registered